LEADER 04935nam 2201417z- 450 001 9910557345903321 005 20220111 035 $a(CKB)5400000000042431 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76517 035 $a(oapen)doab76517 035 $a(EXLCZ)995400000000042431 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aPrevention and Treatment of Sarcopenia 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (288 p.) 311 08$a3-0365-1536-4 311 08$a3-0365-1535-6 330 $aSarcopenia represents the decline in skeletal muscle mass and function with age, characterized by the muscle fiber's quality, strength, muscle endurance, and metabolic ability decreasing, as well as the fat and connective tissue growing.Reduction of muscle strength with aging leads to loss of functional capacity, causing disability, mortality, and other adverse health outcomes. Because of the increase of the proportion of elderly in the population, sarcopenia-related morbidity will become an increasing area of health care resource utilization.Diagnostic screening consists of individuation of body composition, assessed by DEXA, anthropometry, bioelectrical impedance, MRI, or CT scan. Management is possible with resistance training exercise and vibration therapy, nutritional supplements, and pharmacological treatment.The book includes articles from different nationalities, treating the experimental and medical applications of sarcopenia. The consequences of sarcopenia in frailty are treated in relation to other associated pathologies or lesions, as femoral neck fractures and hepatocellular carcinoma. 606 $aMedicine$2bicssc 610 $aaccelerometer 610 $aaerobic exercise training 610 $aaged 610 $aageing fractures 610 $aaging 610 $aanxiety 610 $aapoptosis 610 $abalance 610 $abisphosphonate 610 $abrain-body cross-talk 610 $aclinical 610 $acognition 610 $acomplications 610 $adeconditioning 610 $adecorin 610 $adepression 610 $adiagnosis 610 $adiagnostic criteria 610 $adual-energy X-ray absorptiometry 610 $aechogenicity 610 $aelderly 610 $aelectrical stimulation 610 $aendurance 610 $aepidemiologic studies 610 $aexercise 610 $aexercise intervention 610 $afall risk 610 $afalls 610 $afatigue 610 $afractures 610 $afrailty 610 $ahepatoma 610 $ahip fracture 610 $ahospitalized older patients 610 $ahypertrophy 610 $ainsomnia 610 $aisokinetic dynamometry 610 $alipids 610 $amitochondria 610 $amotivation 610 $amultimorbidity 610 $amuscle mass 610 $amuscle quality 610 $amuscle regulatory factors 610 $amuscle strength 610 $amuscle-mass 610 $amyokine 610 $anutritional screening tools 610 $anutritional status 610 $anutritional supplements 610 $aolder adults 610 $aolder persons 610 $aosteoporosis 610 $aoxidative stress 610 $apanoramic ultrasound 610 $aphysical activity 610 $aphysical functional performance 610 $aphysical therapy 610 $apolypathological patients 610 $apostmenopausal women 610 $aprevalence 610 $aprevention 610 $aprotein intake 610 $aquality of life 610 $arandomized controlled trial 610 $arecovery 610 $arehabilitation 610 $aresistance exercise 610 $aresistance exercise training 610 $aresistance training 610 $arespiratory system 610 $asarcopenia 610 $asedentary behaviour 610 $askeletal muscle 610 $askeletal muscles 610 $asleep duration 610 $asleep efficiency 610 $asleep quality 610 $aspecific force 610 $aspirometry 610 $astrength 610 $asurvival 610 $atelomere length 610 $atransaminases 610 $atreatment 610 $atype 2 diabetes 610 $aurea 610 $avibration 610 $awalking distance 610 $a?-hydroxy-?-methylbutyrate 615 7$aMedicine 700 $aTesta$b Gianluca$4edt$01290179 702 $aTesta$b Gianluca$4oth 906 $aBOOK 912 $a9910557345903321 996 $aPrevention and Treatment of Sarcopenia$93021394 997 $aUNINA